Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 18 | 2025 | 1679 | 1.850 |
Why?
|
| BRCA2 Protein | 5 | 2020 | 50 | 1.710 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2023 | 727 | 1.170 |
Why?
|
| BRCA1 Protein | 4 | 2020 | 58 | 1.160 |
Why?
|
| Genetic Variation | 3 | 2019 | 429 | 1.030 |
Why?
|
| Genetic Testing | 5 | 2023 | 90 | 0.760 |
Why?
|
| DNA Repair | 5 | 2021 | 196 | 0.720 |
Why?
|
| Quantitative Trait Loci | 7 | 2005 | 88 | 0.670 |
Why?
|
| Blood Pressure | 10 | 2005 | 662 | 0.640 |
Why?
|
| Mutation | 9 | 2025 | 1169 | 0.630 |
Why?
|
| Oncogenes | 1 | 2019 | 44 | 0.630 |
Why?
|
| Population Groups | 1 | 2019 | 59 | 0.590 |
Why?
|
| Genes, BRCA2 | 1 | 2018 | 12 | 0.570 |
Why?
|
| Puerto Rico | 14 | 2025 | 1376 | 0.560 |
Why?
|
| Neoplasms | 4 | 2023 | 1341 | 0.530 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2021 | 860 | 0.480 |
Why?
|
| Models, Biological | 1 | 2019 | 711 | 0.470 |
Why?
|
| DNA-Binding Proteins | 3 | 2019 | 557 | 0.470 |
Why?
|
| DNA Methylation | 3 | 2024 | 393 | 0.440 |
Why?
|
| Chromosome Mapping | 12 | 2021 | 198 | 0.430 |
Why?
|
| Ovarian Neoplasms | 4 | 2022 | 406 | 0.420 |
Why?
|
| Rats, Inbred Dahl | 9 | 2005 | 33 | 0.410 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2013 | 4 | 0.410 |
Why?
|
| DNA Repair Enzymes | 1 | 2013 | 22 | 0.410 |
Why?
|
| Genetics, Population | 4 | 2021 | 118 | 0.400 |
Why?
|
| Humans | 40 | 2025 | 42163 | 0.390 |
Why?
|
| Female | 29 | 2025 | 24018 | 0.360 |
Why?
|
| Child Day Care Centers | 1 | 2011 | 11 | 0.350 |
Why?
|
| Education | 1 | 2011 | 60 | 0.340 |
Why?
|
| Epigenesis, Genetic | 3 | 2024 | 274 | 0.340 |
Why?
|
| Child Abuse | 1 | 2011 | 90 | 0.320 |
Why?
|
| Case-Control Studies | 7 | 2020 | 1266 | 0.310 |
Why?
|
| Chromosomes | 4 | 2005 | 44 | 0.300 |
Why?
|
| Prostatic Neoplasms | 3 | 2024 | 1068 | 0.300 |
Why?
|
| Receptors, Estrogen | 4 | 2025 | 177 | 0.260 |
Why?
|
| Middle Aged | 16 | 2025 | 11819 | 0.260 |
Why?
|
| Health Status Disparities | 2 | 2024 | 705 | 0.250 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2025 | 6 | 0.240 |
Why?
|
| Hypertension | 4 | 2005 | 823 | 0.240 |
Why?
|
| Alleles | 3 | 2021 | 352 | 0.240 |
Why?
|
| Gene Frequency | 3 | 2015 | 203 | 0.240 |
Why?
|
| Latin America | 4 | 2022 | 53 | 0.240 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2005 | 26 | 0.230 |
Why?
|
| Tissue Array Analysis | 1 | 2025 | 79 | 0.230 |
Why?
|
| Estrogen Receptor alpha | 1 | 2025 | 120 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2025 | 933 | 0.220 |
Why?
|
| Genome-Wide Association Study | 2 | 2024 | 421 | 0.220 |
Why?
|
| Aged | 12 | 2025 | 7982 | 0.220 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2005 | 142 | 0.210 |
Why?
|
| Genetic Markers | 8 | 2012 | 146 | 0.200 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 53 | 0.190 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 45 | 0.190 |
Why?
|
| DNA, Neoplasm | 1 | 2021 | 92 | 0.180 |
Why?
|
| Biological Clocks | 1 | 2021 | 52 | 0.180 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 40 | 0.170 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2020 | 4 | 0.170 |
Why?
|
| Animals, Congenic | 9 | 2005 | 11 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 139 | 0.160 |
Why?
|
| Skin Pigmentation | 1 | 2020 | 22 | 0.160 |
Why?
|
| Genetic Counseling | 4 | 2022 | 13 | 0.160 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 366 | 0.160 |
Why?
|
| DNA Glycosylases | 1 | 2019 | 17 | 0.160 |
Why?
|
| Quantitative Trait, Heritable | 4 | 2005 | 27 | 0.160 |
Why?
|
| Point Mutation | 1 | 2019 | 98 | 0.150 |
Why?
|
| Colorectal Neoplasms | 1 | 2025 | 502 | 0.150 |
Why?
|
| Mutation, Missense | 1 | 2019 | 88 | 0.150 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 74 | 0.150 |
Why?
|
| Polymorphism, Genetic | 1 | 2020 | 200 | 0.150 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 58 | 0.150 |
Why?
|
| Prognosis | 3 | 2020 | 850 | 0.150 |
Why?
|
| Male | 16 | 2025 | 22779 | 0.140 |
Why?
|
| Florida | 3 | 2025 | 461 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 175 | 0.140 |
Why?
|
| CpG Islands | 3 | 2024 | 107 | 0.140 |
Why?
|
| Introns | 1 | 2018 | 80 | 0.140 |
Why?
|
| Adenoma | 1 | 2018 | 94 | 0.130 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2016 | 9 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2021 | 916 | 0.130 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 2598 | 0.130 |
Why?
|
| Rats | 10 | 2005 | 3701 | 0.130 |
Why?
|
| Chromosomes, Mammalian | 3 | 2005 | 18 | 0.120 |
Why?
|
| Models, Molecular | 1 | 2019 | 875 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 223 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 287 | 0.120 |
Why?
|
| Caribbean Region | 1 | 2015 | 75 | 0.120 |
Why?
|
| Quality of Life | 1 | 2020 | 599 | 0.120 |
Why?
|
| Minority Groups | 1 | 2020 | 663 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 680 | 0.110 |
Why?
|
| United States | 4 | 2022 | 5072 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2020 | 641 | 0.110 |
Why?
|
| Genotype | 2 | 2013 | 796 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2018 | 2485 | 0.100 |
Why?
|
| Risk Factors | 4 | 2017 | 3942 | 0.100 |
Why?
|
| Adult | 8 | 2025 | 13458 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 479 | 0.090 |
Why?
|
| Heterozygote | 1 | 2012 | 107 | 0.090 |
Why?
|
| Microsatellite Instability | 2 | 2025 | 47 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2012 | 845 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 454 | 0.090 |
Why?
|
| Complement C3 | 1 | 2011 | 16 | 0.090 |
Why?
|
| Insurance Coverage | 1 | 2012 | 108 | 0.090 |
Why?
|
| Infertility, Female | 1 | 2011 | 24 | 0.090 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2011 | 35 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 573 | 0.090 |
Why?
|
| Indians, North American | 1 | 2013 | 179 | 0.090 |
Why?
|
| Organizational Case Studies | 1 | 2011 | 31 | 0.090 |
Why?
|
| Insurance, Health | 1 | 2012 | 143 | 0.090 |
Why?
|
| Evidence-Based Practice | 1 | 2011 | 48 | 0.090 |
Why?
|
| Logistic Models | 3 | 2022 | 1001 | 0.080 |
Why?
|
| Patient Selection | 1 | 2012 | 192 | 0.080 |
Why?
|
| Survivors | 2 | 2022 | 152 | 0.080 |
Why?
|
| DNA Damage | 1 | 2012 | 358 | 0.080 |
Why?
|
| Rats, Inbred Lew | 6 | 2005 | 20 | 0.080 |
Why?
|
| Endometriosis | 1 | 2011 | 81 | 0.080 |
Why?
|
| Phenotype | 3 | 2021 | 774 | 0.080 |
Why?
|
| Receptors, Progesterone | 2 | 2022 | 90 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 683 | 0.070 |
Why?
|
| Child | 2 | 2021 | 3381 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2021 | 733 | 0.070 |
Why?
|
| Receptor, erbB-2 | 2 | 2022 | 149 | 0.070 |
Why?
|
| Animals | 10 | 2005 | 16695 | 0.070 |
Why?
|
| Mexico | 2 | 2021 | 286 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2012 | 467 | 0.060 |
Why?
|
| Aorta | 2 | 2005 | 197 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1051 | 0.060 |
Why?
|
| Young Adult | 4 | 2021 | 4936 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2020 | 1574 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2025 | 55 | 0.060 |
Why?
|
| Health Promotion | 1 | 2011 | 691 | 0.060 |
Why?
|
| Reference Values | 1 | 2005 | 207 | 0.060 |
Why?
|
| DNA Primers | 1 | 2005 | 295 | 0.050 |
Why?
|
| Epistasis, Genetic | 1 | 2003 | 18 | 0.050 |
Why?
|
| Proteomics | 1 | 2025 | 363 | 0.050 |
Why?
|
| Base Sequence | 1 | 2005 | 997 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 2803 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2025 | 928 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2022 | 20 | 0.050 |
Why?
|
| Peru | 1 | 2022 | 40 | 0.050 |
Why?
|
| Registries | 1 | 2024 | 431 | 0.050 |
Why?
|
| Germ Cells | 1 | 2022 | 74 | 0.050 |
Why?
|
| Language | 1 | 2023 | 181 | 0.050 |
Why?
|
| Internet | 1 | 2023 | 234 | 0.050 |
Why?
|
| Brazil | 1 | 2021 | 83 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 50 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2020 | 128 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 255 | 0.040 |
Why?
|
| Genomics | 1 | 2021 | 289 | 0.040 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2018 | 32 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2018 | 34 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 28 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 661 | 0.040 |
Why?
|
| Prevalence | 1 | 2022 | 1597 | 0.030 |
Why?
|
| Sex Factors | 1 | 2021 | 1008 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1020 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 1516 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 487 | 0.030 |
Why?
|
| Human Genome Project | 1 | 2013 | 7 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3077 | 0.030 |
Why?
|
| Genome | 2 | 2005 | 149 | 0.030 |
Why?
|
| Genome, Human | 1 | 2013 | 143 | 0.020 |
Why?
|
| Argentina | 1 | 2012 | 14 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 428 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 157 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 85 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2013 | 224 | 0.020 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2011 | 67 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 602 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 236 | 0.020 |
Why?
|
| Culture | 1 | 2012 | 172 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 587 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1058 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2005 | 90 | 0.010 |
Why?
|
| Lod Score | 1 | 2005 | 13 | 0.010 |
Why?
|
| Homozygote | 1 | 2005 | 77 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2005 | 181 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2004 | 27 | 0.010 |
Why?
|
| Breeding | 1 | 2003 | 28 | 0.010 |
Why?
|
| Telemetry | 1 | 2003 | 13 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 190 | 0.010 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2003 | 35 | 0.010 |
Why?
|
| Mice | 2 | 2005 | 6490 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2003 | 128 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 310 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 134 | 0.010 |
Why?
|
| Cardiomegaly | 1 | 2002 | 43 | 0.010 |
Why?
|
| Organ Size | 1 | 2002 | 167 | 0.010 |
Why?
|
| Models, Animal | 1 | 2002 | 149 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 438 | 0.010 |
Why?
|
| Body Weight | 1 | 2002 | 428 | 0.010 |
Why?
|
| Kidney | 1 | 2002 | 363 | 0.010 |
Why?
|